The clinically defined diagnoses of spinal muscular atrophy (also referred to as hereditary motor neuropathy [HMN] ) and Charcot-Marie-Tooth (CMT) disease are useful diagnostic terms for patients with inherited forms of slowly progressive neurogenic weakness and wasting. The presence of clinical or neurophysiologic evidence of sensory involvement, which may be quite modest in some cases, leads to the preferred label of CMT. However, over the last couple of decades, genetic research has revealed many different biochemical mechanisms that underlie the broader clinical descriptions; to date, this genetic heterogeneity is represented by over 41 CMT genes and 8 -10 SMA/distal HMN (dHMN) genes. Furthermore, there are several mutations in the same gene giving rise to either distal SMA (dSMA) or CMT2, again depending on whether sensory changes are detected. Mutations in the gene for glycyl tRNA synthetase (GARS), one of the ubiquitous enzymes responsible for charging aminoacyl-tRNA with its cognate amino acid, have been described in families with dSMA and also in CMT2. 1 Similarly, mutations in the small heat shock protein gene, HSPB1, occur in both "diseases." 2 Whether it is useful to continue using these different labels for very similar phenotypes due to mutations in the same gene is debatable.
In this issue of Neurology ® , Harms et al. 3 provide another example of the coming together of the dSMA and CMT2 phenotype. The authors had previously utilized linkage analyses to localize to 14q32, a gene for dominantly inherited SMA with early childhood onset of weakness and disproportionate involvement of the legs (SMA-LED, OMIM 158600). 4 In this contribution, they sequenced 73 genes within the linked region using modern highthroughput sequencing methods, and landed upon one of the dynein-complex genes (DYNC1H1), where they found a single amino acid change in the tail domain of the protein (p.Ile584Leu). The authors then screened the DYNC1H1 gene for mutations in a series of other patients, and found 2 additional causative mutations in the same domain (p.Lys671Glu and p.Tyr970Cys). In parallel, Weedon et al. 5 studied a family with CMT disease (CMT 2O, OMIM 614228) by exome sequencing, a method that examines only the protein-encoding portions of genes, and landed at the same genetic spot (DYNC1H1 p.His306Arg). Vissers et al. 6 had previously identified a spontaneous mutation in a different protein domain (motor domain) in DYNC1H1 in a child with mental retardation but without SMA, but they found only a single patient, making the causality of the mutation tentative.
Dyneins are well-known neuronal proteins to cell biologists. They are 1 of 2 key "motor" protein groups in cells, the other being the kinesins. They are the "moving trucks" that pick up organelles, proteins, and liposomal packages from one cellular location, promptly delivering them to another, with impressive speed and efficiency. One of the more challenging and long delivery routes in the human body is the neuronal axon, some approaching meters in length. The dominant missense DYNC1H1 mutations might be expected to perturb assembly, stability, or function of dynein filaments and thereby inhibit retrograde axonal transport. In fact, Harms et al. demonstrate this problem directly in patient fibroblasts.
Mutations of DYNC1H1 gene and protein have been well-studied in the mouse. Mouse DYNC1H1 phenotypes are heterogeneous, including "legs at odd angles" (Loa), "crawling" (Cra1), and "sprawling" (Swl). 7, 8 All share motor deficits, but sprawling (Swl) has a prominent sensory phenotype. Intensive study of the Loa mouse has uncovered a broad array of problems, including early-onset proprioceptive sensory neuropathy, muscle spindle deficiency, neuromuscular junction defects, and neuronal migration abnormalities. 9 -11 The mouse studies suggest that the human phenotypes may be more complex than currently thought, and that more phenotypes asso-ciated with DYNC1H1 mutations are likely to follow.
The 3 publications finding human DYNC1H1 mutations share the experimental approach of next generation (nextgen) DNA sequencing. From the 1980s to 2005, DNA sequencing was done on a single gene, single patient basis-it was accurate, generally accessible, but expensive and slow. This led to the current molecular diagnostic thicket, in which different fee-for-service academic laboratories specialize in specific genes. In the specialist clinic, where routine delivery of molecular diagnostics for CMT2 and others is desired, many patients in the clinic left with no molecular diagnosis because testing for big genes with private mutations is only available on a research basis.
Nextgen sequencing permits parallel sequencing for a patient, with the result being that billions of DNA fragments could be sequenced simultaneously. This technological leap involved moving away from one-at-a-time electrophoretic gels, to multitudes of miniscule clones grown (sequenced) individually on a microscope slide. While the data generation was impressive, the process was still expensive and slow, and not accessible for patients in the clinic. The Harms et al. and Weedon et al. studies signal the next transition, to accessible nextgen sequencing. Newly emerging machines can sequence all genes (exomes) in a day, at a reagent cost of about $1,000 each. Importantly, sequencing all genes simultaneously may render irrelevant existing proprietary testing licenses, increasing accessibility and thereby eliminating the existing thicket of laboratories and expense associated with molecular diagnostics. The anticipated exome storm of 2012 will lead to a higher proportion of patients with a defined genetic basis for their disease, and this will accelerate future clinical trials and therapeutics. 
